Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
Bryan A Faller, Barbara BurtnessDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAAbstract: Pancreatic adenocarcinoma is a common malignancy that remains refractory to available therapies. Gemcitabine has long been the standard, first-line agent in advanced disease. The e...
Guardado en:
Autores principales: | Bryan A Faller, Barbara Burtness |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/90b8799b8dd04c1cb305dd9a708ac4e9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles
por: Grapa CM, et al.
Publicado: (2019) -
Aptamer-Conjugated Gold Nanoparticles Targeting Epidermal Growth Factor Receptor Variant III for the Treatment of Glioblastoma
por: Peng L, et al.
Publicado: (2020) -
A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro
por: Han CY, et al.
Publicado: (2013) -
Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab
por: Ma P, et al.
Publicado: (2015) -
Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-active targeting ligand for doxorubicin
por: Liu CW, et al.
Publicado: (2012)